Analysts See 32% Gains Ahead For The Holdings of ESML
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2025
0mins
Should l Buy RXRX?
Source: NASDAQ.COM
ETF Analyst Target Insights: The iShares ESG Aware MSCI USA Small-Cap ETF (ESML) has an implied analyst target price of $50.89, indicating a potential upside of 32.25% from its current trading price of $38.48.
Individual Stock Upside Potential: Notable underlying holdings such as AtriCure Inc, Recursion Pharmaceuticals Inc, and Clover Health Investments Corp show significant upside potential based on analyst targets, with expected increases ranging from 41.37% to 53.23%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RXRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RXRX
Wall Street analysts forecast RXRX stock price to rise
6 Analyst Rating
2 Buy
4 Hold
0 Sell
Moderate Buy
Current: 2.840
Low
5.00
Averages
7.75
High
11.00
Current: 2.840
Low
5.00
Averages
7.75
High
11.00
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Goldman Sachs Optimistic on Nvidia's AI Healthcare Prospects
- Positive Market Outlook: Goldman Sachs' buy rating on Nvidia and a $250 price target imply a 51% upside, reflecting investor confidence in its AI applications within healthcare and life sciences.
- Collaborative Technological Edge: By partnering with life sciences companies, Nvidia can validate its models in labs, leveraging digital twins and simulation to enhance the quality of experiments and manufacturing while reducing costs, thereby strengthening its market position.
- Investment and Applications: In 2023, Nvidia invested $50 million in clinical-stage biotech firm Recursion Pharmaceuticals to develop AI models for accelerating drug discovery, driving technological advancements in the biopharma sector.
- Clinical Trial Efficiency Gains: Recursion's AI technology enables drugmakers to synthesize 90% fewer compounds and reduces the average time to enter human trials from 42 months to 17 months, significantly improving research and development efficiency.
See More
AI's Promising Applications in Healthcare
- Reduced Drug Development Costs: Recursion Pharmaceuticals leverages over 50 petabytes of chemical and biological data through its AI platform to help pharmaceutical companies assess drug performance in hours, significantly lowering the traditional R&D costs close to $900 million, thereby enhancing resource efficiency.
- Strengthened Partnerships: Recursion's collaboration with traditional pharma giants like Sanofi and Roche to conduct virtual testing has driven revenue growth, with expectations of a larger revenue influx in the next fiscal year, indicating its potential in the AI drug development market.
- Tempus AI's Market Performance: Tempus AI empowers healthcare providers with real-time data-driven decision support, achieving fourth-quarter revenue of $367 million, an 83% year-over-year increase, demonstrating strong market demand and customer satisfaction.
- Future Growth Expectations: Analysts have set a target price of $77.93 for Tempus, which is 70% above its current price, reflecting market optimism regarding its future profitability and further enhancing its investment appeal.
See More
Recursion Pharmaceuticals Stock Decline Analysis
- Stock Performance: Recursion Pharmaceuticals (RXRX) closed at $2.94, down 6.67% from the previous session, significantly underperforming the S&P 500's 1.67% decline, indicating weakness in market sentiment towards the company.
- Monthly Decline: The stock has fallen 16.45% over the past month, greatly exceeding the Medical sector's 7.36% and the S&P 500's 6.15% losses, reflecting investor concerns regarding its future profitability.
- Earnings Expectations: The upcoming earnings report is expected to show an EPS of -$0.27, a 46% increase from the prior year, with revenue projected at $20.73 million, up 40.65% year-over-year, indicating potential business growth.
- Analyst Ratings: Currently holding a Zacks Rank of #3 (Hold), Recursion's EPS estimate has increased by 9.98% in the last 30 days, suggesting analysts' growing confidence in the company's short-term performance, despite its industry ranking being in the bottom 40% of over 250 sectors.
See More
Recursion Appoints New Chief Medical Officer
- Executive Change: Recursion announced the appointment of Vicki Goodman as Chief Medical Officer, effective April 6, 2026, succeeding David Mauro; Goodman brings over 20 years of oncology drug development experience, having most recently served as CMO at Mural Oncology, where she advanced its pipeline.
- Extensive Industry Background: Goodman has held senior oncology roles at Merck and Bristol Myers Squibb, leading the development of key drugs such as Keytruda, Opdivo, and Yervoy, showcasing her deep expertise in cancer therapeutics.
- Market Reaction: Following the announcement of this executive change, Recursion's shares fell by 1.86%, indicating market uncertainty regarding the new CMO's impact and investors' cautious outlook on the company's strategic direction.
- Future Outlook: Recursion expects to extend its cash runway into early 2028 while enhancing operational efficiency; although the executive transition may affect short-term market confidence, the long-term strategy remains focused on innovative drug development.
See More
RECURSION PHARMACEUTICALS INC NAMES VICKI GOODMAN AS CHIEF MEDICAL OFFICER, STARTING APRIL 6, 2026
- New Appointment: Recursion Pharmaceuticals has appointed Vicki Goodman as their new Chief Medical Officer.
- Effective Date: The appointment is effective from April 6, 2026.
See More
AI Stocks Face Revaluation and Opportunities Ahead
- Market Revaluation: Recently, AI stocks have faced a revaluation, with Microsoft shares down over 20% from last year's peak and Oracle's shares halved due to concerns over AI infrastructure spending, reflecting skepticism about the technology's value.
- Investor Psychological Cycle: AI is currently in the 'trough of disillusionment' phase, and while performance is poor in the short term, history shows this stage often precedes a recovery, suggesting investors should view this as a long-term buying opportunity.
- Oracle's Growth Potential: Oracle expects its AI infrastructure revenue to grow from $18 billion this year to $144 billion by 2030, nearly three times its total revenue from the last fiscal year, indicating significant potential in its shift to the AI market.
- Google Cloud's Competitive Edge: Google's cloud computing segment is its fastest-growing business, and while AI accounts for only 15% of its revenue, its enterprise-focused capabilities are rapidly increasing market share, indicating strong future growth potential.
See More
Goldman Sachs Optimistic on Nvidia's AI Healthcare Prospects
- Positive Market Outlook: Goldman Sachs' buy rating on Nvidia and a $250 price target imply a 51% upside, reflecting investor confidence in its AI applications within healthcare and life sciences.
- Collaborative Technological Edge: By partnering with life sciences companies, Nvidia can validate its models in labs, leveraging digital twins and simulation to enhance the quality of experiments and manufacturing while reducing costs, thereby strengthening its market position.
- Investment and Applications: In 2023, Nvidia invested $50 million in clinical-stage biotech firm Recursion Pharmaceuticals to develop AI models for accelerating drug discovery, driving technological advancements in the biopharma sector.
- Clinical Trial Efficiency Gains: Recursion's AI technology enables drugmakers to synthesize 90% fewer compounds and reduces the average time to enter human trials from 42 months to 17 months, significantly improving research and development efficiency.
See More
AI's Promising Applications in Healthcare
- Reduced Drug Development Costs: Recursion Pharmaceuticals leverages over 50 petabytes of chemical and biological data through its AI platform to help pharmaceutical companies assess drug performance in hours, significantly lowering the traditional R&D costs close to $900 million, thereby enhancing resource efficiency.
- Strengthened Partnerships: Recursion's collaboration with traditional pharma giants like Sanofi and Roche to conduct virtual testing has driven revenue growth, with expectations of a larger revenue influx in the next fiscal year, indicating its potential in the AI drug development market.
- Tempus AI's Market Performance: Tempus AI empowers healthcare providers with real-time data-driven decision support, achieving fourth-quarter revenue of $367 million, an 83% year-over-year increase, demonstrating strong market demand and customer satisfaction.
- Future Growth Expectations: Analysts have set a target price of $77.93 for Tempus, which is 70% above its current price, reflecting market optimism regarding its future profitability and further enhancing its investment appeal.
See More
Recursion Pharmaceuticals Stock Decline Analysis
- Stock Performance: Recursion Pharmaceuticals (RXRX) closed at $2.94, down 6.67% from the previous session, significantly underperforming the S&P 500's 1.67% decline, indicating weakness in market sentiment towards the company.
- Monthly Decline: The stock has fallen 16.45% over the past month, greatly exceeding the Medical sector's 7.36% and the S&P 500's 6.15% losses, reflecting investor concerns regarding its future profitability.
- Earnings Expectations: The upcoming earnings report is expected to show an EPS of -$0.27, a 46% increase from the prior year, with revenue projected at $20.73 million, up 40.65% year-over-year, indicating potential business growth.
- Analyst Ratings: Currently holding a Zacks Rank of #3 (Hold), Recursion's EPS estimate has increased by 9.98% in the last 30 days, suggesting analysts' growing confidence in the company's short-term performance, despite its industry ranking being in the bottom 40% of over 250 sectors.
See More
Recursion Appoints New Chief Medical Officer
- Executive Change: Recursion announced the appointment of Vicki Goodman as Chief Medical Officer, effective April 6, 2026, succeeding David Mauro; Goodman brings over 20 years of oncology drug development experience, having most recently served as CMO at Mural Oncology, where she advanced its pipeline.
- Extensive Industry Background: Goodman has held senior oncology roles at Merck and Bristol Myers Squibb, leading the development of key drugs such as Keytruda, Opdivo, and Yervoy, showcasing her deep expertise in cancer therapeutics.
- Market Reaction: Following the announcement of this executive change, Recursion's shares fell by 1.86%, indicating market uncertainty regarding the new CMO's impact and investors' cautious outlook on the company's strategic direction.
- Future Outlook: Recursion expects to extend its cash runway into early 2028 while enhancing operational efficiency; although the executive transition may affect short-term market confidence, the long-term strategy remains focused on innovative drug development.
See More
RECURSION PHARMACEUTICALS INC NAMES VICKI GOODMAN AS CHIEF MEDICAL OFFICER, STARTING APRIL 6, 2026
- New Appointment: Recursion Pharmaceuticals has appointed Vicki Goodman as their new Chief Medical Officer.
- Effective Date: The appointment is effective from April 6, 2026.
See More
AI Stocks Face Revaluation and Opportunities Ahead
- Market Revaluation: Recently, AI stocks have faced a revaluation, with Microsoft shares down over 20% from last year's peak and Oracle's shares halved due to concerns over AI infrastructure spending, reflecting skepticism about the technology's value.
- Investor Psychological Cycle: AI is currently in the 'trough of disillusionment' phase, and while performance is poor in the short term, history shows this stage often precedes a recovery, suggesting investors should view this as a long-term buying opportunity.
- Oracle's Growth Potential: Oracle expects its AI infrastructure revenue to grow from $18 billion this year to $144 billion by 2030, nearly three times its total revenue from the last fiscal year, indicating significant potential in its shift to the AI market.
- Google Cloud's Competitive Edge: Google's cloud computing segment is its fastest-growing business, and while AI accounts for only 15% of its revenue, its enterprise-focused capabilities are rapidly increasing market share, indicating strong future growth potential.
See More
